Reddit Posts
$MYNZ, $CVM--- Biotechs Bouncing off their Bottoms
Biotechs with Good News are Running: $CVM, $MYNZ
Mainz Biotech $MYNZ ($1.30) -- Expected news on Colorectal Cancer Detection Study before End of Year
NJ CRC Board Reverses Itself and Fully Approves Curaleaf's Adult Use License Renewals After Legal Challenge
NJ CRC Votes to approve Curaleaf license renewal which was previously denied
MYNZ Multiple Near Term Catalysts Ahead - $50-$75 stock trading at $6/share
MYNZ Multiple Catalysts Ahead $50-$75 stock at $6/share
Advantages of colorectal cancer screening: showing the importance of prenetics products
Rejuvenation of colorectal cancer population highlights the importance of early screening, Prenetics high-efficiency detection products have been launched
Columbia Care receives New Jersey CRC green light to start operations in 2nd cultivation site & for use of post-harvest automation equipment
The next rise - AVL to the moon - supported by government due to energy crisis
NJ Cannabis Trade Association Dispensaries Lack Town Approval to Start Sales Heady NJ
CRC Berates Dispensaries' Bad Adult-use Sales Applications & Impatience Heady NJ
NJ CRC Announces 2019 Medical Cannabis Dispensary License Winners
NJ CRC Releases Webinar on Adult-use Cannabis License Applications
Apparently, Chinese Railway Corporation (CRC) is 1.8 TRILLION+ in debt (!) losing 24 million a day! Shanghai GDP in comparison is only $600 Billion.
$MOTS Has buy rating with avg of 2.00/share. It’s cheap right now. Check it out. Good news today as well!
Motus (MOTS) positive news and a buy rating with price target at avg 2.00 at .61 currently. Great deal
NJ CRC Announces Cultivation, Vertical Winners of 2019 Medical Cannabis Applications
NJ CRC Releases Adult-Use Cannabis Rules Emphasizing Social Equity
AMC+GME and the Hidden Weakness' of Bears selling Naked Old Wine in New Bottles. Why could these Stocks be the Shorts' Achilles' Heel? An American Midwest Gen X Mom has her view on this. She made a breakdown of the The NYSE Threshold Security List for 2020/21. GME ❤️AMC Together Strong 🚀🛰🌖🪐
Exact Sciences - Future Global Leader in Advanced Cancer Diagnostics
Mentions
Company Progress • The DOJ/SEC investigations are closed, and CYDY was not the focus of the case. • The company has treated over 1,600 patients and is submitting its safety profile and supporting data for publication. • The Phase 3 MDR-HIV trial achieved statistical significance. • The Phase 2 MSS-CRC trial builds upon promising basket-trial data showing tumor size reduction, modulation of the tumor microenvironment, and PD-L1 up-regulation—potentially enabling synergistic combinations with checkpoint inhibitors. Management has communicated that PD-L1 data is expected in January 2026, which could pave the way for partnership funding or collaboration opportunities. ⸻ Conclusion Given the company’s strengthened fundamentals, clinical progress, and the closing of its regulatory challenges, CYDY appears significantly undervalued at current levels. Based on peer comparisons alone, a near-term valuation in the $3–$5 per share range seems reasonable even before accounting for additional indications or future developments.
Company Progress • The DOJ/SEC investigations are closed, and CYDY was not the focus of the case. • The company has treated over 1,600 patients and is submitting its safety profile and supporting data for publication. • The Phase 3 MDR-HIV trial achieved statistical significance. • The Phase 2 MSS-CRC trial builds upon promising basket-trial data showing tumor size reduction, modulation of the tumor microenvironment, and PD-L1 up-regulation—potentially enabling synergistic combinations with checkpoint inhibitors. Management has communicated that PD-L1 data is expected in January 2026, which could pave the way for partnership funding or collaboration opportunities. ⸻ Conclusion Given the company’s strengthened fundamentals, clinical progress, and the closing of its regulatory challenges, CYDY appears significantly undervalued at current levels. Based on peer comparisons alone, a near-term valuation in the $3–$5 per share range seems reasonable even before accounting for additional indications or future developments.
Company Progress • The DOJ/SEC investigations are closed, and CYDY was not the focus of the case. • The company has treated over 1,600 patients and is submitting its safety profile and supporting data for publication. • The Phase 3 MDR-HIV trial achieved statistical significance. • The Phase 2 MSS-CRC trial builds upon promising basket-trial data showing tumor size reduction, modulation of the tumor microenvironment, and PD-L1 up-regulation—potentially enabling synergistic combinations with checkpoint inhibitors. Management has communicated that PD-L1 data is expected in January 2026, which could pave the way for partnership funding or collaboration opportunities. ⸻ Conclusion Given the company’s strengthened fundamentals, clinical progress, and the closing of its regulatory challenges, CYDY appears significantly undervalued at current levels. Based on peer comparisons alone, a near-term valuation in the $3–$5 per share range seems reasonable even before accounting for additional indications or future developments.
Company Progress • The DOJ/SEC investigations are closed, and CYDY was not the focus of the case. • The company has treated over 1,600 patients and is submitting its safety profile and supporting data for publication. • The Phase 3 MDR-HIV trial achieved statistical significance. • The Phase 2 MSS-CRC trial builds upon promising basket-trial data showing tumor size reduction, modulation of the tumor microenvironment, and PD-L1 up-regulation—potentially enabling synergistic combinations with checkpoint inhibitors. Management has communicated that PD-L1 data is expected in January 2026, which could pave the way for partnership funding or collaboration opportunities. ⸻ Conclusion Given the company’s strengthened fundamentals, clinical progress, and the closing of its regulatory challenges, CYDY appears significantly undervalued at current levels. Based on peer comparisons alone, a near-term valuation in the $3–$5 per share range seems reasonable even before accounting for additional indications or future developments.
Company Progress • The DOJ/SEC investigations are closed, and CYDY was not the focus of the case. • The company has treated over 1,600 patients and is submitting its safety profile and supporting data for publication. • The Phase 3 MDR-HIV trial achieved statistical significance. • The Phase 2 MSS-CRC trial builds upon promising basket-trial data showing tumor size reduction, modulation of the tumor microenvironment, and PD-L1 up-regulation—potentially enabling synergistic combinations with checkpoint inhibitors. Management has communicated that PD-L1 data is expected in January 2026, which could pave the way for partnership funding or collaboration opportunities. ⸻ Conclusion Given the company’s strengthened fundamentals, clinical progress, and the closing of its regulatory challenges, CYDY appears significantly undervalued at current levels. Based on peer comparisons alone, a near-term valuation in the $3–$5 per share range seems reasonable even before accounting for additional indications or future developments.
CRC calls will be printing money in the future
CRC calls will be printing money in the future
CRC, it is positioned to be a big player in californis
Sure it's cheaper, but ColoAlert is also inferior to Cologuard despite being newer. But the individual test cost isn't really that important. We are talking single payor systems or variations thereof. A stool based CRC test checks for one cancer the prevalence of which is not as high in Europe as in the US. The demand really isn't there. MCEDs will be deployed across whole patient populations and be able to check for many cancers at once. Any cancer except brain cancer is potentially detectable. Even if costs per test might be high, there are substantial cost savings from catching many cancers sooner, as well as happier constituents. This is why the NHS is desperate to support MCEDs and why Mainz is trading under $2.00 and why Cologuard hasn't expanded to Europe.
CRC, OTGLY & RTX are my main 3 positions
I have been invested in this company for several years strictly because the science is game changing. This is not hyperbole, that is how some of the Oncologists that have witnessed the results of Leronlimab has described the results they have seen. In the last 2 years Dr. Jacob Lalezari has turned the ship around from past managements deplorable performance. Dr. Lalezari has cleaned up the mess from past managements mistakes and has everything in order to move this drug forward. Looking forward to seeing results from the current MSS-CRC trial
. a ultra high wealth individual is fully funding our expanded access and and Glioblastoma trials .ABSI has been our secret partner for three years .meeting set with FDA w/ BRIEFING book for mtnbc .we have FAST TRACK DESIGNATION for mTNBC .PRECLINIC SHOWED 98% improvement in lung mets .NEW ARM LL + checkpoint inhibitor FOR PATIENT with PROGRESSING Disease in CRC .doubled overall survival. .mTNBC TRIAL P2 RESUMING PER 10K .mTNBC PTS STILL LIVING 5YRS-P value .0007 .up-regulates Pd-L1 making all patients eligible for checkpoint inhibitors tx .STROKE RECOVERY .reverses fibrosis from any cause p value 0.01 ,leads to funded PF .GATES FUNDING THE HELL OUT OF SACHA .ART+bNAB+LL=HIV cure .Alz trial Jan-filly funded .Long acting partner ABSCI .Berlin scientist just cured the 8th HIV pts requested LL .LH NIH grant .Latch HIV cure trial funded by AMFAR . LL CROSSES BBB &PLACENTA .FcRn mutation blocks CCr5 in fetus .Engaged SYNEOS .Transferred MNFR Tec . Samsung restructured debt til”profitable “
“Finally, I am happy to share a very promising announcement as it relates to a patient who prospectively upregulated PD-L1 after having obtained access to leronlimab through an eIND application submitted by her treating physician. In early 2025, we received a compassionate access request for a patient with mTNBC who was previously unresponsive to treatment with Keytruda. This particular patient had two prior tissue biopsies, both of which were PD-L1 negative. In April, the patient started treatment with leronlimab, and in July blood tests confirmed an increase in PD-L1 levels. Our past clinical observations have shown that upregulating PD-L1 is the first step towards prolonged survival in this patient population and we are encouraged by this readout, which supports our working theory. This is the first of hopefully many PD-L1 upregulation readouts across our CRC and TNBC trial(s) in the coming year. I continue to have high hopes for our upcoming Phase II trials, as well as our expanded access program, as we look to reshape treatment paradigms in solid tumor oncology.”
UK partner gives access to the biggest CRC screening market in Europe
UK partner gives access to the biggest CRC screening market in Europe. Even a small private-network pilot would matter for Mainz Biomed
Q4 CRC top-line still the near-term stock driver
Really interesting update. Having PancAlert move forward alongside CRC definitely makes MYNZ look more like a diversified diagnostics platform. If feasibility reads out positively, it could help reduce single-trial risk and support a stronger long-term valuation case.
$CRC getting upgraded left and right Solid energy play CRC 🚀
$CRC and $TLN - strongest energy plays
AI inferred approximations of simulated physics will work as a CRC/Checksum for Q-bits. Kind of like how the computer makes up ray tracing renders from just a few hit samples rather than chimping all possible ray paths, its the same math... where you end up is probabilistic and AI is great at beating stats of non-linear systems into a polynomial. Cheers.
I feel your pain! I owned it for almost 3 years also. Averaged down to 1.01 and was holding 100,000 shares. I paper handed after the threat of delisting before it dropped to .55 cents. Was able to take the money and invest it in CRC and recouped everything plus. Then all of a sudden the fucken thing becomes a mean stock... The irony... Bought back in 3 days ago with 30k shares and it popped 36%. Got out fast and it felt good. My revenge was complete... Now I'm tempted to buy back in again if it goes down on Monday. I'll never learn... Mwahahaha "evil laugh". True regard i guess...
Cydy has fallen back. But for a molecule that can cure cancer - this is cheap. TNBC and CRC - and many many other potential indications. HIV cure/ Alzheimer’s/ lung and brain cancer
Cydy in Barcelona in July and initiating a CRC kick off hopefully this week. Molecule can cure cancer
My eBay auction ends in 4 HRS 20 MIN - help me out chads 🙏Pokemon Charizard Base Set 2 Holo Rare #4 PSA 10 Gem Mint + PSA CRC Review ✅
This is my $15,000 card only at $3650 for auction rn, I need the Pokemon chads here to bid it 🆙 Search this on eBay if interested: Pokemon Charizard Base Set 2 Holo Rare #4 PSA 10 Gem Mint + PSA CRC Review ✅
I need some Pokemon chads here to buy my card on eBay, it’s up for auction right now! It’s a $15,000 card only at $3,650 for auction rn, search Pokemon Charizard Base Set 2 Holo Rare #4 PSA 10 Gem Mint + PSA CRC Review ✅ LFG
Hey fellow degenerate! 🚀 Got a little something-something cooking on eBay that I figured some of you might appreciate... and maybe even help send 📈. I've got a Pokemon Charizard Base Set 2 Holo Rare #4 PSA 10 Gem Mint + PSA CRC Review ✅ up for grabs. You know what that means. 🔥🐉🔥 Think of the tendies you could buy... or maybe just another even shinier card. 😉 Do your thing, WSB. Let's see this bad boy go to the moon! 🚀🚀🚀 Just search that exact title on eBay: Pokemon Charizard Base Set 2 Holo Rare #4 PSA 10 Gem Mint + PSA CRC Review ✅ No financial advice here, just a friendly heads-up from your fellow ape. 💎🙌 Let's get it! 💪
Can the Pokémon chads on here bid up my item on eBay? Pokemon Charizard Base Set 2 Holo Rare #4 PSA 10 Gem Mint + PSA CRC Review ✅ $15,000 card I need it to sell good for the sub!
I need my friends on here to search my listing on eBay and bid that shit up for me - thanks 🙏 Pokemon Charizard Base Set 2 Holo Rare #4 PSA 10 Gem Mint + PSA CRC Review ✅
how will this be able to compete with cologuard plus which has a sensitivity of 95% and a specificity of 94% for CRC and is already widely available with established insurance coverage?
Exxon can't operate that asset though. No super-major can, they all left the state these past few years since applying California's environmental requirements across all their assets world-wide would put them out of business (and doing so would be necessary to remain in operation there). Chevron, formerly "Standard Oil of California," had been in CA for over 120 years and left entirely, abandoned (I think) six refineries and several oil sites. Exxon and the others majors are also totally gone. The only oil companies still left in California are small ones that mainly operate within the state. CRC is an example. And these only keep a handful of assets running that are still worth operating there, even after all the absurd taxes and environmental regulations are taken into account. So Exxon was essentially forced to sell this. They are bankrolling Sable's legal team and will do business with them if they come online. It's almost like a subsidiary
$CYDY updated Recap - OUR VP/HEAD OF CLINICAL DEVELOPMENT WORKS FOR BILL GATES FOUNDATION & at Cytodyn - .Dr.Sacha has concluded that ART+bNAB+LL=HIV cure 🍹 - CRC trial starting to screen patients - Inflammation trial approved and will lead to proof of concept ,MOA and potentially numerous indications - Mash Now being handled by Dr. Palm in combination with multiple drugs. - Dr.Palmer hired as lead Hepatology expert - Glioblastoma results eminent & can lead to accelerated approval - Alzheimer’s 20pt trial start January anonymous funder may be BILL GATE FOUNDATION ‼️ - Long acting partner with AI capabilities still anonymous - Berlin scientist who just cured the fifth HIV patient requested leronlimab for possible cure - Chronic fatigue syndrome added - waiting NIH long-hauler - Latch HIV cure trial funded by AMFAR - mtnbc is back in play with some pretty major players Dr. pastel, Dr.Ueno, and now a stealth addition of Dr. Clinton yam from MD Anderson - Lironlimab CROSSES BBB AND PLACENTA - Engaged SYNEOS for clinical trials
CYDY updated Recap - OUR VP/HEAD OF CLINICAL DEVELOPMENT WORKS FOR BILL GATES FOUNDATION & at Cytodyn - .Dr.Sacha has concluded that ART+bNAB+LL=HIV cure 🍹 - CRC trial starting to screen patients - Inflammation trial approved and will lead to proof of concept ,MOA and potentially numerous indications - Mash Now being handled by Dr. Palm in combination with multiple drugs. - Dr.Palmer hired as lead Hepatology expert - Glioblastoma results eminent & can lead to accelerated approval - Alzheimer’s 20pt trial start January anonymous funder may be BILL GATE FOUNDATION ‼️ - Long acting partner with AI capabilities still anonymous - Berlin scientist who just cured the fifth HIV patient requested leronlimab for possible cure - Chronic fatigue syndrome added - waiting NIH long-hauler - Latch HIV cure trial funded by AMFAR - mtnbc is back in play with some pretty major players Dr. pastel, Dr.Ueno, and now a stealth addition of Dr. Clinton yam from MD Anderson - Lironlimab CROSSES BBB AND PLACENTA - Engaged SYNEOS for clinical trials
$CYDY updated Recap - OUR VP/HEAD OF CLINICAL DEVELOPMENT WORKS FOR BILL GATES FOUNDATION & at Cytodyn - .Dr.Sacha has concluded that ART+bNAB+LL=HIV cure 🍹 - CRC trial starting to screen patients - Inflammation trial approved and will lead to proof of concept ,MOA and potentially numerous indications - Mash Now being handled by Dr. Palm in combination with multiple drugs. - Dr.Palmer hired as lead Hepatology expert - Glioblastoma results eminent & can lead to accelerated approval - Alzheimer’s 20pt trial start January anonymous funder may be BILL GATE FOUNDATION ‼️ - Long acting partner with AI capabilities still anonymous - Berlin scientist who just cured the fifth HIV patient requested leronlimab for possible cure - Chronic fatigue syndrome added - waiting NIH long-hauler - Latch HIV cure trial funded by AMFAR - mtnbc is back in play with some pretty major players Dr. pastel, Dr.Ueno, and now a stealth addition of Dr. Clinton yam from MD Anderson - Lironlimab CROSSES BBB AND PLACENTA - Engaged SYNEOS for clinical trials December 2024 Letter to Shareholders
Try CYDY: Recap - OUR VP/HEAD OF CLINICAL DEVELOPMENT WORKS FOR BILL GATES FOUNDATION & at Cytodyn - .Dr.Sacha has concluded that ART+bNAB+LL=HIV cure 🍹 - CRC trial starting to screen patients - Inflammation trial approved and will lead to proof of concept ,MOA and potentially numerous indications - Mash Now being handled by Dr. Palm in combination with multiple drugs. - Dr.Palmer hired as lead Hepatology expert - Glioblastoma results eminent & can lead to accelerated approval - Alzheimer’s 20pt trial start January anonymous funder may be BILL GATE FOUNDATION ‼️ - Long acting partner with AI capabilities still anonymous - Berlin scientist who just cured the fifth HIV patient requested leronlimab for possible cure - Chronic fatigue syndrome added - waiting NIH long-hauler - Latch HIV cure trial funded by AMFAR - mtnbc is back in play with some pretty major players Dr. pastel, Dr.Ueno, and now a stealth addition of Dr. Clinton yam from MD Anderson - Lironlimab CROSSES BBB AND PLACENTA - Engaged SYNEOS for clinical trials
Try looking into CYDY: Recap - OUR VP/HEAD OF CLINICAL DEVELOPMENT WORKS FOR BILL GATES FOUNDATION & at Cytodyn - .Dr.Sacha has concluded that ART+bNAB+LL=HIV cure 🍹 - CRC trial starting to screen patients - Inflammation trial approved and will lead to proof of concept ,MOA and potentially numerous indications - Mash Now being handled by Dr. Palm in combination with multiple drugs. - Dr.Palmer hired as lead Hepatology expert - Glioblastoma results eminent & can lead to accelerated approval - Alzheimer’s 20pt trial start January anonymous funder may be BILL GATE FOUNDATION ‼️ - Long acting partner with AI capabilities still anonymous - Berlin scientist who just cured the fifth HIV patient requested leronlimab for possible cure - Chronic fatigue syndrome added - waiting NIH long-hauler - Latch HIV cure trial funded by AMFAR - mtnbc is back in play with some pretty major players Dr. pastel, Dr.Ueno, and now a stealth addition of Dr. Clinton yam from MD Anderson - Lironlimab CROSSES BBB AND PLACENTA - Engaged SYNEOS for clinical trials
CYDY Recap - OUR VP/HEAD OF CLINICAL DEVELOPMENT WORKS FOR BILL GATES FOUNDATION & at Cytodyn - .Dr.Sacha has concluded that ART+bNAB+LL=HIV cure 🍹 - CRC trial starting to screen patients - Inflammation trial approved and will lead to proof of concept ,MOA and potentially numerous indications - Mash Now being handled by Dr. Palm in combination with multiple drugs. - Dr.Palmer hired as lead Hepatology expert - Glioblastoma results eminent & can lead to accelerated approval - Alzheimer’s 20pt trial start January anonymous funder may be BILL GATE FOUNDATION ‼️ - Long acting partner with AI capabilities still anonymous - Berlin scientist who just cured the fifth HIV patient requested leronlimab for possible cure - Chronic fatigue syndrome added - waiting NIH long-hauler - Latch HIV cure trial funded by AMFAR - mtnbc is back in play with some pretty major players Dr. pastel, Dr.Ueno, and now a stealth addition of Dr. Clinton yam from MD Anderson - Lironlimab CROSSES BBB AND PLACENTA - Engaged SYNEOS for clinical trials
Try CYDY Recap - OUR VP/HEAD OF CLINICAL DEVELOPMENT WORKS FOR BILL GATES FOUNDATION & at Cytodyn - .Dr.Sacha has concluded that ART+bNAB+LL=HIV cure 🍹 - CRC trial starting to screen patients - Inflammation trial approved and will lead to proof of concept ,MOA and potentially numerous indications - Mash Now being handled by Dr. Palm in combination with multiple drugs. - Dr.Palmer hired as lead Hepatology expert - Glioblastoma results eminent & can lead to accelerated approval - Alzheimer’s 20pt trial start January anonymous funder may be BILL GATE FOUNDATION ‼️ - Long acting partner with AI capabilities still anonymous - Berlin scientist who just cured the fifth HIV patient requested leronlimab for possible cure - Chronic fatigue syndrome added - waiting NIH long-hauler - Latch HIV cure trial funded by AMFAR - mtnbc is back in play with some pretty major players Dr. pastel, Dr.Ueno, and now a stealth addition of Dr. Clinton yam from MD Anderson - Lironlimab CROSSES BBB AND PLACENTA - Engaged SYNEOS for clinical trials
Try CYDY Recap - OUR VP/HEAD OF CLINICAL DEVELOPMENT WORKS FOR BILL GATES FOUNDATION & at Cytodyn - .Dr.Sacha has concluded that ART+bNAB+LL=HIV cure 🍹 - CRC trial starting to screen patients - Inflammation trial approved and will lead to proof of concept ,MOA and potentially numerous indications - Mash Now being handled by Dr. Palm in combination with multiple drugs. - Dr.Palmer hired as lead Hepatology expert - Glioblastoma results eminent & can lead to accelerated approval - Alzheimer’s 20pt trial start January anonymous funder may be BILL GATE FOUNDATION ‼️ - Long acting partner with AI capabilities still anonymous - Berlin scientist who just cured the fifth HIV patient requested leronlimab for possible cure - Chronic fatigue syndrome added - waiting NIH long-hauler - Latch HIV cure trial funded by AMFAR - mtnbc is back in play with some pretty major players Dr. pastel, Dr.Ueno, and now a stealth addition of Dr. Clinton yam from MD Anderson - Lironlimab CROSSES BBB AND PLACENTA - Engaged SYNEOS for clinical trials
CYDY updated Recap - OUR VP/HEAD OF CLINICAL DEVELOPMENT WORKS FOR BILL GATES FOUNDATION & at Cytodyn - .Dr.Sacha has concluded that ART+bNAB+LL=HIV cure 🍹 - CRC trial starting to screen patients - Inflammation trial approved and will lead to proof of concept ,MOA and potentially numerous indications - Mash Now being handled by Dr. Palm in combination with multiple drugs. - Dr.Palmer hired as lead Hepatology expert - Glioblastoma results eminent & can lead to accelerated approval - Alzheimer’s 20pt trial start January anonymous funder may be BILL GATE FOUNDATION ‼️ - Long acting partner with AI capabilities still anonymous - Berlin scientist who just cured the fifth HIV patient requested leronlimab for possible cure - Chronic fatigue syndrome added - waiting NIH long-hauler - Latch HIV cure trial funded by AMFAR - mtnbc is back in play with some pretty major players Dr. pastel, Dr.Ueno, and now a stealth addition of Dr. Clinton yam from MD Anderson - Lironlimab CROSSES BBB AND PLACENTA - Engaged SYNEOS for clinical trials
This stock is extremely risky right now. They just [failed to meet Nasdaq's minimum bid requirements and stockholder equity requirements](https://finance.yahoo.com/news/mainz-biomed-announces-stock-split-134500760.html). The reverse split is a desperate move to stay listed. The 1-for-40 split will take them from 80.1 million shares to just 2 million - that's massive dilution. Their partnership with Thermo Fisher is promising for developing their CRC screening tests. But they're burning through cash fast with clinical trials and no real revenue yet. The ColoAlert test isn't even FDA approved in the US. The cancer diagnostics market is huge but MYNZ is competing against giants with way more resources. Their tiny market cap and delisting risks make this more of a lottery ticket than an investment right now. Not financial advice but I'd wait until they sort out their Nasdaq compliance issues before considering a position. The fundamentals aren't there yet.
Mainz Biomed's ColoAlert® test is a game-changer for CRC detection, boasting a 97% accuracy rate and promising early diagnosis! $MYNZ is the new technology.
I'll say this: Murphy is saying the right things here but it's harder than it looks. The liquor lobby is powerful, and now they are going to be lobbying individual cannabis commissioners. The rollout of the New Jersey cannabis industry was very, very sloppy. Even though they may now have a lot of the kinks worked out (since they were sorta building the plane as they were flying it with the cannabis rollout), they're still being expected to do so without getting a single extra dollar in funding to do so. It wouldn't surprise me if, in six months' time, the CRC \*still\* hasn't issued the rules and regulations and everything remains in limbo. source: me, the guy who wrote the article linked here
I'll say this: Murphy is saying the right things here but it's harder than it looks. The liquor lobby is powerful, and now they are going to be lobbying individual cannabis commissioners. The rollout of the New Jersey cannabis industry was very, very sloppy. Even though they may now have a lot of the kinks worked out (since they were sorta building the plane as they were flying it with the cannabis rollout), they're still being expected to do so without getting a single extra dollar in funding to do so. It wouldn't surprise me if, in six months' time, the CRC \*still\* hasn't issued the rules and regulations and everything remains in limbo. source: me, the guy who wrote the article linked here
The Albanian law prescribes that children between ages 6- 16, should go to school. Article 32 of the CRC Conventions guarantees children the right to be protected from “performing any work that is likely to be hazardous or to interfere with the child's education
Dude, you cite a 2012 article for treatment options? Antiquated paper from over 10yrs ago. At least cite the latest NCCN. And it is a unique agent, other forms of IL-15 have had mixed success, with the modification to this superagonist it mimics endogenous IL-15 signaling in trans with enhanced binding affinity. Compared to other common gamma chain cytokines, IL-2 being the most ubiquitous, you don't have Treg proliferation. Here they were approved for BCG resistant/refractory NMIBC. The options in this space are: 1. Cystectomy 2. Intravesicular chemos like Valrubicin (approved for BCG-refractory CIS) 3. Pembrolizumab (for BCG-unresponsive, high-risk NMIBC with Tis (with or without papillary) tumors or with BCG- unresponsive, high-risk NMIBC with high-grade papillary Ta/T1 only tumors without Tis who are ineligible for or have elected not to undergo cystectomy) 4. And Nadofaragene firadenovec-vncg (for BCG-unresponsive, high-risk, NMIBC with CIS (with or without papillary) or with BCG-unresponsive, high-risk, NMIBC with high-grade papillary Ta/T1 only tumors without CIS In terms of comparisons, very generally: Pembro's 12 months, the disease-free survival (DFS) rate was 43.5% (95% CI, 34.9%-51.9%) and the median DFS was 7.7 months (95% CI, 5.5-13.6). With a CR rate at 3 months of 41% in Keynote-057. Nado had a CR of 51% (95% CI, 41%-61%). Compared to N-803's estimated 12-month DFS rate of 55.4% (95% CI, 42.0%-66.8%). The median DFS was 19.3 months (95% CI, 7.4-not reached). And an initial CR rate of 71%. It's not a systemic therapy like Pembro and has better comparative data than Nado. I would anticipate it becoming the main player for BCG-resistant/refractory NMIBC. Which has an incidence of 50-60k/yr in the US alone, approximately 30% of those will be BCG-resistant/refractory after 12 months. They're submitting approvals for 6 other countries upfront (UK, Canada, Italy, etc) and are evaluating the agent as a first line tx for NMIBC as well as studies as salvage for Lung and CRC. They're also using the agent in some of their other NK-based portfolio. I think they've got some genuine upside potential with this agent, let alone the rest of their pipeline.
Don't take my word for it. Google "reddit ad analytics" and it will show you subreddits of redditors who tried advertising on reddit... they all EXPECTED poor results and it's exactly what they got. Low performance, low CTR, low CRC. It's like fishing. With Facebook you can cast a massive net over a body of water where you can see a lot of fish. Reddit it like a thousand small ponds, some lakes, and trying to decide where the fish are. Maybe AI can solve this? But as of right now, the yields are too low for it to be worth the effort and investment for ad buys.
Long post, but I find this stuff fascinating lol I saw the title and thought this was about the NY reservation businesses. Those mfs are moving literal *tons* of sketchy California/Oklahoma black market bud, oil and edibles. The store that I go to has some legit, sealed, CA-licensed, top shelf eighths that I've verified with the west coast growers, but I don't really trust any of the extracted stuff (ex: CRC was for $5-10/g) I frequently shoot the shit with the owners of these shops when they're on site and some of their stories are hilarious. The competition is insane. The closest Rez shop (Dispo A) to my home town is 25 highway miles away and is right off the exit. They were the first one with billboards leading into the exit. They started advertising $50-60/ounce sales when NY legalized and you'd see other shops throwing up ads for $40...$30...$25... They've been racing to the bottom and now it's stuck at $10 for shitty last-years outdoor. Dispo A bought an adjacent property next to their closest competitor (Dispo B, 10 second walk between the two). Dispo A built a bigger retail store and put a massive white wall fence directly in front of the Dispo B to the point where you can't see the shop from the road. Dispo B responded by putting a huuuuge electronic sign on top of their building. So now you get off the exit, see 3-4 competing billboards and drive past Dispo A2, Dispo B and Dispo A1. They're all within a 20 second walk from each other. Highway---Exit----A2-B-A1----------------------------------C----D--E---------F---- etc etc. *Both* of Dispo A's stores are attached to tax-free gas stations and I'm pretty sure they own them outright by now. If you fill up for more than $20, you can bring the receipt inside for a free pre roll. They're totally washing money with the fuel sales, but I give em a ton of credit. It's a civilized version of the wild west and the marketing tactics are ballsy as hell. Most of the owners that I've talked to are normal, friendly people, but you can tell that they were probably involved in something before NY went legal. You don't just start one of these things up without being plugged in... I usually go to Dispo B because they have some real CA designer brands at $50/eighth. I also saw fancy psilocybin chocolate bars behind the counter this week. Budtender said he's tried em and they're legit 😂 Margins have to be through the roof on the mid grade commercial bud that I see most people buying. No sales tax, no testing, no tracking. All cash business. Just gotta have a decent supply chain of vacuum-sealed priority mail packs. It's so fucking funny to watch these people throw a cheap structure together within a week and start pumping $5-10m+ sales out of a single location. Probably should have thrown my weedstock money into a partnership with one of em lol The NY rollout has been terrible overall, but there are certain counties in NY full of boomer council members that are "still considering the risks of bringing a legal store into our sacred, god-loving towns". This is the only reason why the Rez shops are raking in cash. I know a lot of consumers that would rather drive 5 minutes down the street and pay a bit extra for tested, licensed product. I'm curious if anyone here has also been watching/experienced this side of the NY "industry". It's been really interesting to see it develop. /storytime
Read something at IR website. There is a lot of risk in this scenario and I share my thoughts: - BOT/BAL is an new immunotherapy combo (anti PD1/CTLA4). This combination is already used in some solid tumours (melanoma) with a very challenging safety profile - CRC market is mainly driven by biomarkers (RAS) in 1st and 2nd line, mainly combining an biologic (like cetuximab or bevacizumab) plus a chemo based on 5-FU. Immunotherapies in this setting have a very small market - ACTIVATE study design is for 3rd line comparing BOT/BAL against lonsfurf or regorafenib. Only if they prove superiority in this setting I think they may have success in ph3. The chemo break story in this 3rd line is a strong message for HCPs. In summary: I’ve started a small position and will watch closely ph2 results. After ACTIVATE results we may be able to think more clearly how BOT/BAL profile will be in CRC.
AGEN has a very interesting pipeline. Not only in the BMS compound but also CRC market has a very interesting opportunity. Going to study a little bit more thanks for sharing.
Shortage was more so like a case of items got ruined in transit arrive broken. Most people would just throw it out but you were supposed to scan it out and follow steps to dispose of it properly. The main issue I saw was they had a salvage house and something they called CRC. CRC was their returns center that sent the item back to the manufacturer and it wouldn’t count as shortage. If the label for CRC wasn’t right next to the items actual label and everything securely closed it counted as shortage. Everything could be perfect except the sticker location and it was shortage. If certain items weren’t bagged on return shortage. Their system for tracking stuff is kinda garbage and it gives the oppurtunity for “lost items” basically moved from the front of store to back stock but never scanned into location at back stock. That item gets sold but it was never put in back stock so it’s shortage. The salvage house was also a bit picky as well with what they sent. A lot of clearance items aren’t handled properly become lost items that get sold but you don’t know. Another big thing causing shortage was at the register with target you can price challenege or stuff missing barcodes gave the clerk an oppurtunity to create shortage if they didn’t do some extra work to find the item being sold or the actual correct way to price challenge
Lost $10k CRC; lost $25 k Chesapeake. Shale is big oil. 100x on MSFT
In 2022, all stocks were being re-evaluated due to bond yields spiking up. The TNX was rising fast which lowered the forward P/E for all stocks. Long-term bond yields affect banks’ revenue. Short-term bond yields affect their expenses. Because the yield curve was inverted for more than 3 months, that signaled some sort of instability in the financial system (not an economic recession, per se). In 2023, BAC and bank stocks went down due to a sentiment scare where retail and small funds are selling their bank shares for short-term treasury securities. That’s about to end soon. That said, Bank of America took a risk from 2020-2022 with increasing their commercial real estate loans. In Q1 2023, the Federal Reserve stated their concerns over CRC. In BAC’s Q1 earnings, their provisions for credit losses increased by over $1 billion… not the smartest move that BAC has done. Their net income is fine though. So it’s not exactly in danger here, except for someone’s banking career.
100% support this. CRC has done nothing but allow the black/grey markets to attain complete dominance and the only licensed businesses are souleless MSOs. nj has the most expensive products, the worst selection of edibles, no beverages
https://thebusinessprofessor.com/en_US/business-transactions/short-swing-profit-rule-definition Among other things would let insiders buy and sell very quickly and hold the profits. For example, there was about 90 minutes between the CRC renewing Cura's permits on Monday before it got out to the market, resulting in a 6% boost to price. Under normal rules if an insider bought before the news was spread, then sold right after, they'd have to return the profits to the company under this rule.
Booker has been vocal as fuck about being anti MSO and blocking businesses and reform in the industry. Then his staffer gets put on the NJ CRC with power to vote on licenses. Do you not see how this borders on conflict of interest?
I mean it’s not like Booker has kept quiet about his ambitions to block progress unless there’s social justice and equity and they give out licenses to previously arrested individuals harmed by the war on drugs. You cant be that daft. Booker’s tone and logic mirrors that if the NJ CRC if you watched last week’s meeting and then the marijuana moment article on Booker. Literally parroting the same points, tone, and sentiment. If it looks like a duck, and it quacks like a duck, it’s probably a duck.
Jesus stop squealing like a pig. It’s a developing story. But here you go to calm your emotion down By yours truly NJ CRC - cant find a better source than that https://twitter.com/newjerseycrc/status/1381705384923107336?s=46&t=NJUI5NkByhJWO-kp0jGhDg
Your morning Twitter rumor, validity not confirmed yet. https://twitter.com/cannasseursio/status/1648292131750961153?s=46&t=NJUI5NkByhJWO-kp0jGhDg The single “nay” vote on NJ’s CRC commission for Curaleaf’s license renewal was by commissioner Barker, who is allegedly a former staffer for none other than Big Pharma’s mascot Mr “LayMyselfDown” Senator Cory Booker.
CRC made a hasty political decision barring any reason last week. Curaleaf's cultivation facility supplies whole sale cannabis to multiple social equity license holders in NJ. CRC basically put the jobs of 500 people in jeopardy by not renewing the licenses, even though it was recommended for renewal. The Curaleaf Russian FUD and BS allegations from self-proclaimed journalists and social justice keyboard warriors on Twitter has been spearheading the Curaleaf hate we've seen lately.
New Jersey CRC going into emergency session, anyone following? Can’t get any audio/video.
Thinking this through. Reports suggest the CRC took issue with closure of the Bellmawr cultivation site (under suspicion of union busting per reports from 3 weeks ago), which needed to be approved by the CRC under the Regs (see Section 17:30-9.2). And yesterday the CRC mentioned that the application had inaccuracies. I bet the application didn’t cover closure of the Bellmawr facility because Curaleaf hadn’t committed to close it when the application was submitted several months ago. Curaleaf should’ve sought the CRC’s approval to close Bellmawr as soon as the decision was made and — critically — also amended the renewal application.
Absolutely inexcusable. And the CRC took issue with inaccuracies in their renewal application. Their Government Affairs, Legal, and Compliance teams are incompetent.
ChatGPT: If a company's recreational sales license is not renewed by the Cannabis Regulatory Commission (CRC), the company can challenge the decision through an administrative appeal process. The first step would be to review the reasons for the non-renewal provided by the CRC and identify any areas of disagreement. The company can then file a written appeal with the CRC within the specified time frame, typically within 15 to 30 days of receiving notice of the non-renewal. The appeal would generally be heard by an administrative law judge, who would review the evidence and arguments presented by both the company and the CRC. The judge would then make a recommendation to the CRC on whether the non-renewal should be upheld or overturned.
>Considering they are really the only realistic ev play and non evs are getting banned in the next 10 years it's a retirement play. This would be true.... if it was 2006. However, since 2010, you are far behind the ball. GM, Ford, and Chrysler have all been investing massively into EVs since 2010. By 2011, they were all on a massive hiring plan and that included sponsoring battery technician degrees so that people could go to school for free and get paid by them while doing so. They have been taking the long term route. However, turning the wheels of progress for massive companies takes time. They don't want to rush it. GM and Ford have been doing autonomous testing since 2014 (?) in anticipation. They have been designing these vehicles for over a decade now. Most of that is the internal electrics and the best way to swap the plants for full production. They were starting major swaps for 2019 with a 2020 release date. They pushed it back when it was found that to meet the demand schedule, they would need a few more factories. This pushed it back to 2023 due to the pandemic and people buying so many cars. Ford built their first new factory in 40 years completed this year specifically for EVs. 2023 is the year for the majority of EV releases if not by 2024. Tesla isn't the only game in town and is no where close to the cheapest or best quality. >Cyber truck, a new car that puts it within the tax credit range, those could easily keep the growth rate up there The Ford lightning already delivered 13k in October of 2022. 2023 production rates are expected at 150k. Chevy already has 150k reservations for the Silverado EV slated for spring of 2023. Production looks like it will keep up. It starts at 40k well within the tax credit and price range of many weekend warriors. >not to mention other sources of income if they get the Tesla Bots going No offense, if Sony can't get the Aibo going, Tesla is screwed on this. The designer of the Aibo literally developed the code checking method for data transfer called CRC specifically for the Aibo system. They crammed a full vision system on 10 mb. Tesla is decades away at best. >If there's more growth in their Tesla Solar and/or battery packs Not likely. The Chinese are beating them on technology. They failed to bid on solar efficiency upgrades that were offered from a Washington based research team. This research gave Chinese companies a major win over US manufacturers. They don't do enough R&D work let alone research to make the major breakthroughs needed. This isn't "program it better", it is fundamentally making the major changes necessary. Think Theranos not Paypal. >higher margins if prices of parts fall faster than the prices of the cars do. They have constant production issues that are systemic. This isn't going to go well for them. >1 year perspective, terrible buy, use stop loss, swing trade, manage risk. 15-30 year outlook, buy the way The last 3 years were the buy period. The next 4 years were potentially a buy period if gas prices dropped and the economy went down massively. Now, it is the time to short Tesla until the stock hits near 0. After said point, you buy it hoping for a buy out or Tesla to magically fix its own issues.
CRC would need to beat Germany if they draw then Spain wins by goal diff
Weirdly, goal differential is more important than head to head. So if it’s a draw, Germany and Japan both finish with 4 points and Germany has to beat CRC by 2 goals. Or beat CRC by 1 goal, but score more than Japan (e.g. 3-2 win and Japan 2-2 tie.)
They're CHECKSUMS, like CRC-32 or SHA-256 or the last digit of your credit card. Period.
This is how the next financial collapse happens. The CRC CokeRat Collapse
as someone who has a CRC certification and looking at graduate schools (biostats or data science), what is your position and current recommendations to further pursue the clinical trials industry
>ACTIVIST INVESTOR KIMMERIDGE ENERGY MANAGEMENT HAS 4% STAKE IN CALIFORNIA RESOURCES CORP, PUSHING FOR CHANGES-SOURCES $CRC ^\*Walter ^Bloomberg ^[@DeItaone](http://twitter.com/DeItaone) ^at ^2022-08-15 ^06:00:21 ^EDT-0400
You've never heard of CRC? It's the toolkit in a can!
My nightmare scenario is this: I keep investing and dollar cost averaging in the ultimate faith that, like every other time, the stock market will eventually come roaring back. However... I can actually imagine a scenario wherein our political system enters a crisis so deep that something calamitous comes out of it. Imagine that the Supreme Court next year rules that only State Legislatures can appoint electors. Republican states then disregard their vote totals and send electors to DC who support Trump or another Republican candidate. Republicans, who now control the House of Representatives by a narrow margin, accept those fake electors and appoint a Republican president despite Biden or another democrat winning both the popular vote and the electoral college. The nation is plunged into chaos as the Biden White House refuses to accept the fake electors and riots erupt all over the country. Our hyper-polarized country is now on the verge of, dare I say, civil war. The Supreme Court, who has recently overturned long-standing precedent after long-standing precedent, is no longer respected as a neutral, impartial institution, but simply another partisan actor, can't arbitrate the dispute. The destruction of our institutions in pursuit of selfish interests, so brazenly attempted under Trump, has finally become complete. Our country is no longer a functioning democracy. Armed vigilante groups start "policing" what they think is right. Looking for "BLM," "Antifa," "Drag Queens," anyone teaching "CRC," or whatever boogymen they are told are ruining the country, white nationalist groups start appearing more and more often to intimidate minority communities. More and more people arm themselves. You can see where this is going.
>\[...\] expanded its adult use shopping hours at both of its Cannabist locations in Deptford and Vineland to the maximum number of hours allotted by the New Jersey Cannabis Regulatory Commission (CRC). > >In addition to the new 270,000-square-foot cultivation, manufacturing and processing facility, the Company also operates a 50,000-square-foot facility, also located in Vineland. The Company has a third retail location in development in New Jersey, which is expected to open later in 2022.
Nice. Thanks for the commentary and source. Good to hear. Hopefully the CRC agrees and grants approval.
As of April 13th, it seems the cultivation expansion construction is complete but waiting for approval. There Arizona cultivation started in Dec 2021 and announced it's first sales today so 6 month lag from approval. It sounds like they are expecting to be able to sell rec before the first harvest from the cultivation expansion. "Ayr does have local approval for three adult-use dispensary locations and a 70,000-square-foot cultivation facility that is complete and awaiting regulatory approval. While the company would have liked to win early approval, its financial expectations for the state are modeled on May 24 approval, according to Sandelman. The team is working closely with the state’s regulators, and Sandelman remains confident that Ayr will receive approvals at the May CRC meeting." [Source](https://www.newcannabisventures.com/ayr-wellness-gears-up-to-leverage-new-assets-following-acquisitive-streak/)
NJ CRC email update: Last Thursday, the first day of adult-use sales in New Jersey, the state’s 12 participating dispensaries sold cannabis and cannabis products to 12,438 recreational cannabis customers for a total gross sale of nearly $1.9 million. Sales of medicinal cannabis products have also been strong over the last 30 days with approximately 64,000 ounces of products dispensed to patients and their caregivers. On April 20 – the day before adult-use sales began – ATCs dispensed 5,400 ounces of medicinal cannabis and cannabis products across New Jersey. In the five days following the beginning of adult-use sales an additional 7,500 ounces were dispensed to patients. “We expected sales to be substantial and the data shows that the market is effectively serving both adult-use consumers and patients,” said Jeff Brown, executive director of the New Jersey Cannabis Regulatory Commission. “We continue to monitor inventory and access for patients and are prepared to take enforcement action against any ATC that does not meet the requirements for patient access and supply.” While lines have been steady at all the dispensaries, there has not been any substantiated reports of supply problems for medicinal cannabis patients. The NJ-CRC continues to monitor and respond to complaints to ensure patients have adequate supply and access. The New Jersey Cannabis Regulatory Commission establishes and enforces the rules and regulations governing the licensing, cultivation, testing, selling, and purchasing of cannabis in the state.
NJ CRC meeting going into executive session for private discussion: Chairman: "So we're fucking over cannabis companies again, right?" "Oh yeah, big time. Fuck 'em" "Perfect, great job again guys!"
I have so little faith that the CRC will approve sales for the existing MSOs today. Really hoping I’m wrong but I foresee more can-kicking for the sake of them “levelling the playing field”
At least it's something. Anything to light the fire under the incompetent CRC is good news in my books.
Puts on CRC As I see the stock gained 7%. I'm sad it had a reverse stock split I presume, as a couple years ago it was literally penny stock
NJ is a shit show, today was a disaster. BUT the CRC did schedule a “special meeting “ for April so maybe we get approval of rec sales then
Meeting is on 3/24, thursday. Last meeting CRC said 8 or so i think were in approval process. IDK how long that lasts. Optimistic would be April 1 maybe? Pessimistic June? FWIW Murphy is budgeting $4million in tax revenue from legal rec by July 1st so fo4 that to happen the stores need to open soon.
The CRC test is complete garbage. Natera has poor specificity. They don't allow testing more than every 3 months because the odds of a false positive become unacceptable for repeat testing. You're going to lose a lot of money.
No shit. I mudlog a lot of their CA spinoff company, CRC. I have seen their ticker on oil stocks picks consistently. I just have an aversion out of principle lll
As disclosed in the Company's news release dated December 9, 2021, regulatory approvals in Massachusetts, New York, Maryland and Florida necessary to close the Company's previously announced recapitalization transaction ("Recapitalization Transaction") remain outstanding. Subsequent to the Company's acquisition of MPX NJ, prior regulatory approval from the CRC for the change of beneficial ownership of MPX NJ that would result from the Recapitalization Transaction is now required in New Jersey as a condition to closing under the Restructuring Support Agreement dated July 10, 2020, as amended.
They were instructed to open rec by 2/22. BUT they just started applications for new rec stores. New rec stores probably won’t open until the fall. That leaves the established dispensaries, who have been begging to sell to recreational buyers. CRC said they need to meet the existing medical demand. Curaleaf said they have too much inventory, they are running out of storage space and it is going to expire so they need to press it into oils. So there is zero reason that rec sales aren’t open TODAY other than the CRC being completely disorganized
Join the CRC call today and ask them https://www.nj.gov/cannabis/about/meetings/
The Mrs and I will be be going to this one but mostly to network with growers, we're applying for Class 5 Retail in March. With respect to rec sales, we already know 4 current licensees have certified that they have enough product to begin rec sales already, but the CRC has been silent. I do wonder if they're trying to let rec stores open first before letting the MSOs have that pie all to the themselves, but I don't see that happening before the summer.
I do agree with the idea of going with the "safer" options both theologically and theoretically it is not wrong to go with large caps and $SPY but I do think it's good to get into small and mid caps to have a more balanced portfolio such as $ANF $MX $CRC $SHEN $MBHCF are such stocks I'm looking into
I think it would be nice to hear more information/sources when Manish says things like "NJ looking like it could be further delayed" and on New York- "I'm hearing some people saying mid-2023, even some people talk now about 2024". Who are saying these things and why? My understanding is by February the NJ CRC needs to set a rec sales start date, so hopefully we have more clarity on that soon.
Imo zero. The CRC supposedly has some level of “proof” that medical demand can be met but isn’t allowing dispensaries to prove their capacity as far as I know. CRC is a clusterfuck, I listened to their zoom and it’s just layer upon layers of bureaucratic bullshit
>The enabling marijuana legalization legislation signed into law by Gov. Phil Murphy last year directs the CRC to begin adult use marijuana sales before Feb. 22, with 30-day notice beginning Jan. 23. >But there's a catch. The CRC is yet to issue any licenses for recreational marijuana sales, so even if sales are approved as of Feb. 22, there won't be any dispensaries selling it.
CRC is my favorite timeline deviant. I mean variant.
This article states sales are legally supposed to start 2/22/22. However, CRC is slacking on issuing rec licenses to existing medical dispensaries. Hopefully they surprise us. [https://www.app.com/story/news/local/new-jersey/marijuana/2022/01/11/nj-marijuana-legal-weed-sales-held-up-cannabis-regulatory-commission/9158935002/](https://www.app.com/story/news/local/new-jersey/marijuana/2022/01/11/nj-marijuana-legal-weed-sales-held-up-cannabis-regulatory-commission/9158935002/)
Washington's marijuana industry is crashing because of low prices from competition between producer/processors and rising mark ups from the retailer. From the beginning of "i502" up until about a year ago, a 3x to 3.5x mark up was industry standard. If you wanted a $20 gram of of oil on the shelf, you sell it for $6.33 to $6.66/g to the store. (6.66 x 3 = ~$20) . Now since everyone and their momma need to do "30% off the store!" every other day, mark ups are closer to 4x to 5x. So the same $6.67 gram of oil is now closer to $5. ($5 x 4 = $20). This is happening for ALL products across the board. Also, "CRC" and "auto flowers" have also had a hand in crashing prices. 2 years ago you could sell oil blacker than the Knights Watch from GoT for $3.33/g all day everyday. Now with CRC, the $10 (shelf price) oil looks like the $60 oil. The quality of oil has gone up and the prices go down. Autoflower allows outdoor growers to get an entire extra harvest (sometimes 2) compared to full term plants. Extra supply with no extra demand added. Flower prices are rock bottom, trim/biomass is rock bottom, and concentrates are rock bottom. There's simply too much material and not enough consumption. Most people don't understand the difference between markets like Florida and Washington/Oregon. One is a state approved Monopoly with inflated prices and margins and the other is a competitive market. I remember doing a Kush Marketplace tradeshow in Oregon in like 2018ish and there were quite a few cannabis farmers switching from THC to CBD because of low prices.